T. Rowe Price Associates’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$22.2M Sell
453,602
-14,952
-3% -$730K ﹤0.01% 941
2025
Q1
$23.9M Sell
468,554
-40,650
-8% -$2.07M ﹤0.01% 911
2024
Q4
$23M Sell
509,204
-50,542
-9% -$2.28M ﹤0.01% 960
2024
Q3
$20.8M Sell
559,746
-46,930
-8% -$1.74M ﹤0.01% 983
2024
Q2
$18.6M Sell
606,676
-33,191
-5% -$1.02M ﹤0.01% 979
2024
Q1
$18.6M Sell
639,867
-358,436
-36% -$10.4M ﹤0.01% 989
2023
Q4
$27.5M Sell
998,303
-104,142
-9% -$2.87M ﹤0.01% 866
2023
Q3
$24.7M Sell
1,102,445
-974,489
-47% -$21.8M ﹤0.01% 869
2023
Q2
$84.5M Buy
2,076,934
+359,169
+21% +$14.6M 0.01% 561
2023
Q1
$83.2M Buy
1,717,765
+433,376
+34% +$21M 0.01% 552
2022
Q4
$49M Sell
1,284,389
-182,804
-12% -$6.98M 0.01% 665
2022
Q3
$73.7M Sell
1,467,193
-173,793
-11% -$8.72M 0.01% 548
2022
Q2
$65.7M Sell
1,640,986
-77,472
-5% -$3.1M 0.01% 792
2022
Q1
$64.1M Sell
1,718,458
-388,103
-18% -$14.5M 0.01% 885
2021
Q4
$83.9M Buy
2,106,561
+1,501
+0.1% +$59.8K 0.01% 821
2021
Q3
$78.3M Sell
2,105,060
-7,608
-0.4% -$283K 0.01% 848
2021
Q2
$89.3M Sell
2,112,668
-44,206
-2% -$1.87M 0.01% 829
2021
Q1
$102M Sell
2,156,874
-58,143
-3% -$2.75M 0.01% 771
2020
Q4
$135M Sell
2,215,017
-54,500
-2% -$3.33M 0.01% 626
2020
Q3
$106M Sell
2,269,517
-188,909
-8% -$8.83M 0.01% 639
2020
Q2
$125M Buy
2,458,426
+405,589
+20% +$20.6M 0.02% 572
2020
Q1
$91.6M Sell
2,052,837
-1,985,150
-49% -$88.6M 0.01% 596
2019
Q4
$194M Buy
4,037,987
+288,469
+8% +$13.9M 0.03% 486
2019
Q3
$127M Sell
3,749,518
-117,771
-3% -$3.98M 0.02% 553
2019
Q2
$174M Buy
3,867,289
+342,747
+10% +$15.4M 0.02% 499
2019
Q1
$133M Buy
3,524,542
+772,296
+28% +$29.1M 0.02% 565
2018
Q4
$94.5M Buy
2,752,246
+259,461
+10% +$8.9M 0.02% 625
2018
Q3
$117M Buy
2,492,785
+1,824,417
+273% +$85.7M 0.02% 619
2018
Q2
$22.5M Buy
+668,368
New +$22.5M ﹤0.01% 1165
2016
Q1
Sell
-8,390
Closed -$272K 2524
2015
Q4
$272K Buy
+8,390
New +$272K ﹤0.01% 2194